Bernstein Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to $390
Portfolio Pulse from Benzinga Newsdesk
Bernstein analyst William Pickering maintains an Outperform rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and raises the price target from $380 to $390.
August 04, 2023 | 10:55 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bernstein analyst maintains an Outperform rating on Vertex Pharmaceuticals and raises the price target from $380 to $390.
The news of Bernstein maintaining an Outperform rating and raising the price target for Vertex Pharmaceuticals indicates a positive outlook for the company. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100